Prima Biomed Releases Quarterly Shareholder Newsletter, Update on "CANVAS" Study Progress
Published: Oct 04, 2012
SYDNEY, AUSTRALIA--(Marketwire - October 03, 2012) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN:US74154B2034) ("Prima," the "Company") today released its quarterly Shareholder Newsletter available on the company website at http://primabiomed.com.au/investor/investor_update.php.
The Shareholder Newsletter provides an overview of the Company's operations, strategy and forthcoming clinical data.
Prima also updates the progress on the CANVAS trial. To date, 16 patients have been randomized on the trial in the US and Australia. CANVAS has been approved by regulators in the US, Australia, Belarus, Belgium, and Ukraine. Ethics committee approvals have been granted at several centers in the US, Australia, Austria, Belarus, Bulgaria, Estonia, Germany, Latvia, Lithuania, Poland, Romania, and Ukraine. Trial sites may start patient recruitment only after regulatory clearance, applicable ethics approval, finalization of contract negotiations with the site, and completion of Prima's training and initiation procedures which assure quality compliance of the trial conduct. Prima will maintain regular updates to the CANVAS study on the US National Institutes of Health clinical trial registry at www.clinicaltrials.gov.
About Prima BioMed
Prima BioMed is a globally active biotechnology company headquartered in Australia. As a leader in personalized bio-therapeutic products for cancer, Prima is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell product currently in clinical trials for ovarian cancer patients who are in remission.
The CANcer VAccine Study ("CANVAS") is a multi-center, randomized, and placebo-controlled study of CVac in late-stage, mucin 1 positive, epithelial ovarian cancer patients who have undergone optimal surgery and achieve complete remission after first-line chemotherapy. 1000 patients will be recruited to CANVAS at over 100 hospitals throughout Australia, the USA, Europe, and Asia to have 800 evaluable study patients go through dosing. The study objectives are to ascertain if CVac, as compared to a placebo, is able to improve the time patients remain in remission before tumor progression (progression-free survival) and extend the overall survival of patients. Safety parameters, quality of life impact, manufacturing quality, and additional laboratory assessments will also be investigated.
CANVAS has been designed for a robust analysis of the clinical and statistical significance of CVac treatment such that, dependent on positive data outcomes, CANVAS may lead to registration of CVac in one or more geographies.
For further information please contact:
Mr. James Moses
+61 (0) 420 991 574
Ms. Kathy Galante
Burns McClellan Inc.
+1 (212) 213-0006
Mr. Axel Muhlhaus
+49 (0) 69 905505-52